Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, not just today’s reading.
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
Shares of ADMA Biologics are up 4.01% at $10.11. The company is worth $2.26B, number 2693 out of 3132 on our list.
The 52-week range is $7.21 to $20.46. Today's price is about 22% of the way from the low to the high. Holders are behind 28.1% over twelve months, but up 9.8% across the last three months.
Price is above the 50-day average ($9.44) but below the 200-day ($11.70); RSI is 59, and the last 30 sessions moved at roughly 41% annualized volatility.
Valuation works out to 14.4 times trailing earnings.
3 analysts follow the stock and the average call is "buy". The mean target, $15.67, sits 55.0% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 3 factors below, ranked against the 3132 U.S. stocks BeStock covers.
Cheaper on P/E than most of BeStock’s coverage scores higher.
Trading closer to its 52-week high than most peers scores higher.
3 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
ADMA is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2021-01-04, the strategy has returned 389% (231.1% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $15.67, 55.0% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $12.63, so shares trade 20.0% below that estimate.
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | +6.4% | Bullish |
| Price vs 50-day average | +7.1% | Bullish |
| Price vs 200-day average | -13.6% | Bearish |
| 50-day vs 200-day | 50d below 200d | Bearish |
| RSI (14) | 59.5 | Bullish |
| MACD (12,26,9) | 0.17 | Bullish |
| Bollinger band position | 85% | Bullish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Oct 5, 2026 10:20 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 3,132 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
$10.11 is the latest print for ADMA, a move of +4.01% against yesterday's close of $9.72. Today's low and high so far: $9.62 and $10.19.
Equity value comes to $2.26B at the current price. By that measure it is number 2693 of the 3132 names in our coverage.
Buyers pay 14.4 times the last twelve months of profit (EPS $0.60).
The year's floor is $7.21 and the ceiling $20.46. Shares are 50.6% away from that ceiling.
Our data shows no dividend paid by ADMA Biologics over the trailing twelve months.
Of 3 analysts, 67% say buy, 33% hold and 0% sell. Price targets average $15.67, with the most cautious at $12.00 and the most optimistic at $18.00.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on ADMA.